Hemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGM
03 Juni 2024 - 8:00AM
RNS Regulatory News
RNS Number : 5037Q
Hemogenyx Pharmaceuticals PLC
03 June 2024
3 June 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx
Pharmaceuticals" or the "Company")
Posting of Annual Report & Notice of
Annual General Meeting
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical group, confirms that the Annual Report
and Accounts for the year ended 31 December 2023, the Notice of the
Annual General Meeting ("AGM") and a Form of Proxy will be posted
to shareholders today and are available on the Company's website
at
https://hemogenyx.com/investors/annual-half-year-reports/.
The AGM is to be held on 27 June
2024 at 2.00 pm BST at the offices of SP Angel Corporate Finance
LLP, Prince Frederick House, 35-39 Maddox Street, London W1S
2PP.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as platform technologies
that it uses as engines for novel product development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOAAMMTTMTTJBII
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
